Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (August 2025)
95 slides from Coloplast A/s Class B's roadshow presentation, August 2025
Slide 1: Roadshow presentation 9M 2024/25: Making life easier
Roadshow presentation 9M 2024/25 Making life easier Strive25: Sustainable Growth Leadership Fikria, User, Continence Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q3 with 7% organic growth and 28% EBIT margin; unchanged FY guidance
Q3 with 7% organic growth and 28% EBIT margin1. Unchanged FY 24/25 guidance on organic growth and EBIT margin Revenue growth Q3 2024/25 highlights • Organic growth was 7% and reported growth in DKK was 1%. Reported growth was negatively impacted by currencies Reported revenue (mDKK) Organic growth (
Slide 4: Q3 organic growth of 7% driven by Chronic Care and broad regional contributions
Q3 organic growth of 7% driven by the Chronic Care businesses and broad regional contributions Q3 2024/25 revenue by business area Q3 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area mDKK growth ar
Slide 5: Ostomy Care organic growth of 6% in Q3
Ostomy Care organic growth of 6% in Q3, with broad-based growth contribution across regions, except for China Ostomy Care performance Q3 2024/25 highlights • Q3 organic growth was 6% and reported growth was 2%, with solid contribution across regions ex. China: • In Europe, growth was broad-based wit
Slide 6: Continence Care grew 8% in Q3 with Luja as main contributor
Continence Care grew 8% in Q3 with Luja as the main contributor to growth, driven by the male catheter Continence Care performance Q3 2024/25 highlights • Q3 organic growth was 8% and reported growth was 3%, with solid contribution across all regions. • Growth in Europe was driven by solid contribut
Slide 7: Voice & Respiratory Care grew 9% in Q3
Voice & Respiratory Care grew 9% in Q3 driven by continued good momentum in both Laryngectomy and Tracheostomy Voice & Respiratory Care performance Q3 2024/25 highlights • Q3 organic growth was 9% and reported growth was 8%. • Laryngectomy delivered double-digit growth, driven by an increase in pati
Slide 8: Advanced Wound Care grew 4%, hit by product return in China
Advanced Wound Care grew 4%, negatively impacted by a product return in China dressings and slower growth for Kerecis in Q3 Advanced Wound Care performance Q3 2024/25 highlights • Q3 organic growth was 4% and reported growth was -8%, which includes 8%-points negative impact from the Skin Care divest
Slide 9: Interventional Urology grew 4% in Q3
Interventional Urology grew 4% in Q3, driven by good momentum in the US Men’s Health business Interventional Urology performance Q3 2024/25 highlights • Q3 organic growth was 4% and reported growth was 1%. • Growth in Q3 was driven by good momentum in the US Men’s Health 7 business, driven by the Ti
Slide 10: Q3 reported revenue grew 1% with Skin Care divestment and currency impact
Q3 reported revenue grew 1% with ~1%-pts negative impact from the Skin Care divestment and ~4%-pts negative impact from currencies Q3 2024/25 Revenue development (mDKK) Q3 2024/25 highlights • Reported revenue increased by DKK 73 million or 1% vs. last year. • Organic growth was 7% or DKK 454 millio
Slide 11: EBIT margin of 28% in Q3
EBIT margin of 28%1 in Q3, driven by a lower level of distribution costs compared to last year, offset by timing of administration costs Q3 2024/25 EBIT margin development before special items (%) Q3 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourabl
Slide 12: Adjusted FCF was DKK 3,327 million in 9M
Adjusted FCF was DKK 3,327 million in 9M, with a FCF-to-sales ratio of 16% FCF development1 9M 2024/25 highlights • Free cash flow for 9M 2024/25 was an inflow of DKK 3,519 million, 90 93 compared to an outflow of DKK 186 million last year. Last year’s FCF was 84 81 83 77 impacted by the tax payment
Slide 13: FY 2024/25 financial guidance unchanged on organic growth and EBIT margin
FY 2024/25 financial guidance on organic growth and EBIT margin* unchanged. Reported growth now expected at 3-4% GUIDANCE 2024/25 GUIDANCE (DKK)1 KEY ASSUMPTIONS • Negative impact from the preventative and voluntary product return in Advanced Wound Dressings in China of around DKK 80 million, impact
Slide 14: Two proposed US CMS rules: competitive bidding and skin substitutes
Two proposed rules announced by the US CMS recently – competitive bidding for Chronic Care and fixed payment for skin substitutes Chronic Care Biologics Proposal • Proposed rule on Competitive Bidding for chronic care • Proposed fixed payment of $125/cm² for all skin categories substitute products i
Slide 15: Immaterial impact from tariffs expected
Immaterial impact from tariffs expected as a significant share of our products are currently exempt from tariffs Chronic Care Voice & Respiratory Care No exposure – products for the No exposure – products for the management of chronic care conditions are management of chronic care conditions are cur
Slide 16: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Fikria | CC user
Slide 17: Coloplast has five business areas with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2023/24 by segment Group revenue 2023/24 by geography 1 Continence Care 1 32% European Ostomy Care markets 35% 54% Other developed markets 29% DKK 4 DKK 27.0bn 27.0bn Interventional Urology 10% 1 5 Emerging Voice & market
Slide 18: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Our brands Ostomy Care People who have had a part of their Adhesive ostomy bags SenSura® Mio digestive or urinary system redirected to an Supporting products Brava® opening in the abdominal wall Contine
Slide 19: The Chronic Care model secures predictable revenue and stable growth
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 9 8 8 8 8 8 8 7 7 7
Slide 20: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Healthcare reforms Growing elderly population Economic restraints drive increases customer base for reimbursement reforms, Coloplast products introduction of tenders, Limiters and lower treatment cost Drivers 02. 02.
Slide 21: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Emerging Ostomy Continence Voice & Respiratory Interventional Advanced 1 1 1 4 5 X Global market position Care Care Care (Laryngectomy) Urology Wound Care Addressable market 44-48bn 2
Slide 22: Playing an active role in the care continuum
We are building a company that plays an active role in the care continuum and addresses unmet needs in the market Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer Clinical Data preference prefer
Slide 23: Strive25 strategy and long-term financial guidance
Our Strive25 strategy supports continued long- term value creation through revenue and earnings growth Long-term financial guidance 8-10% more than 30% organic growth EBIT margin p.a.1 beyond 2024/25 1 Raised to 8-10%, from previously 7-9%, on July 7 as a result of the acquisition of Kerecis, expect
Slide 24: Incremental investments of up to 2% of revenue in Strive25
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas – up to 2% of revenue in incremental OPEX investments Investments made in H1 of Strive25 Continued investments in H2 of
Slide 25: Strive25: M&A plays a bigger role
Strive25: M&A plays a bigger role as we seek to secure long-term growth and value creation options beyond 2025 Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion Early-stage & adjacencies technologies Examples: 2022 US direct-to-consumer TFL Drive DME dealers1 (
Slide 26: Key enablers supporting the Chronic Care commercial model
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Coloplast® Care Superior, clinically differentiated products Direct to Consumer Consumer Clinical Direct Businesses preference Data preference Data & Digital tools Payer preference
Slide 27: Direct business in Chronic Care drives outcomes and growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply +30 cou
Slide 28: Clinical Performance Programme to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face Continence Care – preventing UTIs remains one of the biggest unmet needs Ostomy Care – Leakage remains the biggest challenge for our users 45 % of users describe UTIs as their greatest challenge
Slide 29: Luja with Micro-hole Zone Technology addresses UTI risk factors
Luja , our new catheter platform with Micro-hole Zone Technology addresses key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk factors
Slide 30: Data on Heylo is promising
Data on Heylo is promising. Pivotal clinical study showed improvement in quality of life and a 31% reduction in leakage Pre-pilot study on Heylo Pivotal clinical studies on Heylo Product performance & user experience1 First pivotal clinical study on Heylo4, conducted in Germany showed: Using Heylo s
Slide 31: Profitability during Strive25 impacted by inflation, PPA and Kerecis
Profitability during Strive25 has been negatively impacted by inflationary headwind, PPA amortizations related to acquisitions and dilution from Kerecis Gross Profit development, % Cost item % of revenue* • FY 22/23 Gross Profit negatively impacted by inflationary headwind on input costs (raw materi
Slide 32: Global Operations Plans have delivered value since 2008
Global Operations Plans (GOPs) have delivered significant value since 2008, supporting Coloplast’s industry leading profitability 2008 2009 2012 2017 2020 2023-2026 Turn-around GOP1 GOP2/GOP3 GOP4 GOP5 GOP6 Focused Operational Operational Step change Fit for the future Excellence Excellence executio
Slide 33: Global Business Support and IT landscape enables scaling
A global Business Support and IT landscape enables Coloplast to scale faster and efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / acco
Slide 34: EBIT margin development: growth, scalability, cost discipline, investment
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: • Leverage effect on fixed costs e.g. >30% distribution, admin and R&D costs especially d
Slide 35: Continued strong free cash flow development during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation YTD 24/25 effective tax rate Net working capital CAPEX1 affected by Kerecis IP transfer Extraordinary tax rate CAPEX DKKm Net working capital, % of revenue Ordinary tax rate Depreciation and amortisation, % o
Slide 36: Attractive cash returns despite investments and acquisitions
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical and Kerecis acquisitions Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm)1 Share buy-back Pay-out ratio (%)2 • Coloplast returns excess liqui
Slide 37: Stable shareholder returns through growth and margin
We believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin Value creation levers 27% • Stable market trends in our Chronic Care business • Innovative product portfolio and new product launches • Strong Coloplast Care retention program and DtC a
Slide 38: Introduction to Kerecis
Introduction to Kerecis An emerging category leader in the biologics wound care segment
Slide 39: Kerecis adds a long-term growth business
With Kerecis, Coloplast adds a long-term growth business, uniquely positioned to support long-term value creation Compelling strategic rational Kerecis financial assumptions Performance of Kerecis • Three-year revenue CAGR of ~30% until FY 2025/26 • Attractive gross margin level, accretive to Colopl
Slide 40: Entering the biologics segment in advanced wound care
We enter the biologics segment, expanding our footprint in the US and transforming our presence in the global advanced wound care market Addressable advanced wound care market by segment Addressable advanced wound care market Gelling Fibers (advanced dressings and biologics) Advanced dressings 4-6 W
Slide 41: Kerecis technology platform based on gently processed fish skin
Kerecis is transforming wound healing with its clinically differentiated technology platform based on gently processed fish skin Kerecis key business highlights Started in 2009, with headquarters and manufacturing in Iceland Proprietary product platform based on intact fish skin DKK 1,026m Revenue f
Slide 42: Fish skin uniquely positioned for wound healing in humans
Fish skin – uniquely positioned for wound healing in humans Kerecis fish-skin technology – gently processed, preserving its similarity to human skin Fish Skin for Human Skin* Epidermis Dermis 100 µm 100 µm Advantages of the fish-skin technology: • High resemblance to human skin: similar three-dimens
Slide 43: Compelling clinical evidence with 50+ publications
Comparative RCTs & Second-Degree Burns Angiogenesis and Compelling clinical Prospective Clinical and Excised Full- Faster Epithelialization Trials Thickness Burns evidence with 50+ 1. Evaluating Intact Fish Skin 1. Staubach et al. J Clin Med 1. R. Stone II et al. Biomedicines (2024) 2. Kerecis vs Pr
Slide 44: Sustained strong growth momentum at Kerecis
Sustained strong growth momentum through proven commercial model and a purpose-driven organisation Kerecis revenue distribution, FY 2023/24 Sustained strong growth through: By wound type: By care setting: By geography: • Continued strong growth in the US across wound types and care settings US • Acc
Slide 45: Introduction to Atos Medical (Voice and Respiratory Care)
Introduction to Atos Medical (Voice and Respiratory Care) The global market leader in laryngectomy Joakim | Provox Life user
Slide 46: Atos Medical leads the attractive chronic laryngectomy market
Atos Medical is the leader in the attractive chronic laryngectomy market, with strong growth and profitability outlook Key market and business highlights Key financial assumptions Laryngectomy Tracheostomy • Organic growth 8-10% Procedures per year ~50,000 ~1,000,000 Organic growth • Laryngectomy: h
Slide 47: Atos improves lives of patients after Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, and the surgery performed in the advanced stages patient applies the Heat- and Moisture Exchanger (HME)
Slide 48: Significant untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 49: Tracheostomy patients have similar needs as laryngectomy patients
Tracheostomy patients have similar needs as laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 50: Leading intimate healthcare: Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Laura | IC user
Slide 51: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 3.0% ~137.9 billion DKK (~22 billion USD) market 1.0% 5.0% cap @ ~612.00 DKK p
Slide 52: Capital structure
Capital structure Highlights Net interest-bearing debt Overall policy is that excess liquidity is returned to shareholders through a combination of dividends (paid bi-annually) and 2.5x 2.6x share buy-backs (expected at DKK 500m per year; no buy- 2.4x back in FY 23/24 and FY 24/25). 2.3x Interest be
Slide 53: 9M organic growth of 7% with broad-based contribution
9M organic growth of 7% with broad-based contribution, except for Interventional Urology which was impacted by the product recall 9M 2024/25 revenue by business area 9M 2024/25 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth S
Slide 54: 9M reported revenue grew 4%
9M reported revenue grew 4%, with ~1%-point detraction from both divested operations and currencies 9M 2024/25 Revenue development (mDKK) 9M 2024/25 highlights • Reported revenue increased by DKK 836 million or 4% vs. last year. • Organic growth was 7% or DKK 1,325 million, driven by: +836 mDKK • Br
Slide 55: Reported EBIT margin of 27% in 9M
Reported EBIT margin of 27%1 in 9M, driven by a higher level of distribution costs, partly offset by a lower level of administration cost 9M 2024/25 EBIT margin development before special items (%) 9M 2024/25 highlights • Gross margin was 68%, on par with last year. • Positive impact from a favourab
Slide 56: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 33.4 33.0 36.8 32.3 32.6 36.2 32.0 31.5 31.2 34.6 34.7 32.3 32.2 32.4 31.7 30.7 32.2 30.1 29.0 28.7 28.2 26.5 26.1 26.3 25.3 23.6 23.7 23.4 4.2 4.5 4.6 4.6 4.4 5.0 5.2 5.0 5.1 5.0 5.0 4.1 3.9 3.5 3.9 3.8 3.9 3.8 3.6 3.4 3.3 18/19 19/20 20
Slide 57: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care1 10 8 7 19 6 6 16 7 5 6 10 4 5 11 14 5 10 9 9,546 9 10 8,620 9,024 1 7,841 7,415 4 9 9 1 2,424 2,674 2,775 1,939 2,110 2,097 2,117 NA 1,706 1,203 20/21 21/22 22/23 23/24 YTD 24/25 20/21 21/22 2
Slide 58: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets1 21 20 8 12 10 5 8 6 5 4 9 8 4 5 3 6 5 15 6 4 7,746 13,908 14,750 6,480 12,916 11,535 5,775 5,912 11,261 4,785 20/21 21/22 22/23 23/24 YTD 24/25 20/21 21/22 22/23 23/24 YTD 24/25 Emerging Markets Coloplast group2 15
Slide 59: Segment operating profit
Segment operating profit Segment Operating Profit DKKm (Excludes shared/non-allocated costs) Segment Operating Profit Margin (%) Chronic Care Interventional Urology Voice & Respiratory Care1,2 Adv. Wound Dressings Biologics1,3 Ostomy and Continence Care 38 35 34 34 36 58 57 58 58 59 49 39 40 43 37 3
Slide 60: 9M 2024/25 PPA amortisation impact on EBIT margin
9M 2024/25 Atos Medical and Kerecis PPA amortisation impact on EBIT margin 32% 3% 29% 29% 1% 27% 1% 26% 1% DKK 241 DKK 235 DKK 134 DKK 646 million million million million 9M 2024/25 Special items EBIT margin PPA EBIT margin Amortisation excl. EBITA Depreciation EBITDA EBIT margin after total1 before
Slide 61: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2024/25 and hedging policy Revenue FX exposure 2024/251) 12 months exposure from 10% initial exchange rate drop1) Other 18% EUR -740 34% USD -240 CNY, JPY, AUD, BRL & ARS 10% GBP -370 -220 13% HUF 0 GBP 150 25% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance f
Slide 62: No significant healthcare reforms expected in FY 2024/25
No significant healthcare reforms expected in FY 2024/25. The expectation of long-term price pressure of up to 1% p.a. is unchanged Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • US Biologics: CMS review of coverage and payment for skin substitutes. Final ruling • France:
Slide 63: Coloplast CARE increases retention and compliance
Coloplast CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website w
Slide 64: Direct-to-Consumer marketing program
With our Direct-to-Consumer marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Introduce innovative products Ensure product accessibility Ensure successful experience 64
Slide 65: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 65
Slide 66: Interventional Urology revenue balanced geographically and across business areas
Interventional Urology revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 18-20bn market FY 23/24 growing 4-6% annually 10% Coloplast position, FY 23/24 of Coloplast sales Bladder Health & Endourology Men
Slide 67: Interventional Urology business areas and select products
Coloplast Interventional Urology consists of four business areas Men’s Women’s Bladder Health Endourology & Surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Test
Slide 68: Strong presence in Interventional Urology with room to capture share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 69: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 70: Portfolio expansions with TFL Drive and Intibia
Portfolio expansions in adjacent segments with TFL Drive and Intibia provide strong growth potential for Interventional Urology Target Adjacencies Target Adjacencies AUS ED OAB BPH AUS POP Core SUI Coloplast Endo Consum- Endo TFL Drive Laser ables • Launched in Q4 2021/22 Prostate • State of the art
Slide 71: Intibia gives option to enter the OAB market
With Intibia , Coloplast obtained an option to enter the attractive OAB market worth around 1bn USD. Launch expected in FY 2025/26 Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB sym
Slide 72: Wound & Skin Care 2025 strategic plan (Advanced Wound Dressings)
The Wound & Skin Care 2025 strategic plan (Advanced Wound Dressings) Expand in the US Win in Europe Lead in China Outgrow market and deliver competitive profitability Reach full 3DFit Selectively potential invest Selectively expand Drive commercial portfolio excellence 72
Slide 73: In US Ostomy Care we continue to win across the patient pathway
In US Ostomy Care we continue to win across the patient pathway We have invested across the care continuum in Strive25 … and are now seeing acute share gains translate into the community US OC patient pathway Bags and plates acute share +7%-pts Acute Post-acute Community 2019 (pre-GPO) H1 23/24 MAT
Slide 74: Awarded access to key GPOs in US Ostomy Care
Coloplast has been awarded access to key GPOs, ensuring a level playing field in ~75% of acute accounts in US Ostomy Care Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute members1 Estimated Contract Contract Contract Acute share2 expiry date length type
Slide 75: US Continence Care: upgrade to hydrophilic catheters with Luja
In US Continence Care, we drive the upgrade of the market to hydrophilic catheters and aim to set a new standard of care with Luja We are driving the upgrade to hydrophilic-coated Existing US IC reimbursement categories; new, dedicated codes for hydrophilic catheters in the US catheters to be implem
Slide 76: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 77: 9M 24/25 progress on key sustainability ambitions
9M 24/25 progress on key sustainability ambitions Improving products and packaging Reducing emissions Responsible operations 9M FY 9M FY 9M FY Ambition 24/25 23/24 Ambition 24/25 23/24 Ambition 24/25 23/24 100% 90% 2.0 2.1 Recyclable 74% Scope 1+2 emissions 1.7 Lost time injury packaging1 reduction
Slide 78: Introducing Ostomy Care
Introducing Key products Ostomy Care • Between 2 and 3 million people live with a stoma globally, ~2/3 in the developed markets • Up to around 300,000 stoma surgeries per year in developed markets and China Disease areas SenSura® Mio in black SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • C
Slide 79: Ostomy Care Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Heylo Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape • Market size of DKK 4-5bn Digital leakage notification system Designed for leakage Reducing skin problems Elastic so it follows the • Market growth of 6-
Slide 80: Introducing Continence Care
Introducing Key products Continence Care • Intermittent catheters for management of urinary retention and collecting devices for management of urinary incontinence Luja Intermittent catheter with SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex • Around 6 million people live with urinary reten
Slide 81: Introducing Bowel Care
Introducing Key products Bowel Care Market fundamentals • Market size for transanal irrigation of DKK ~1bn • Around double-digit market growth Peristeen® Light Peristeen® Plus Peristeen® Transanal Irrigation Transanal Irrigation Transanal Irrigation Disease areas 175ml Launched in 2024 Launched in 2
Slide 82: Introducing Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total laryngectomy, a typical treatment for advanced Provox® Life laryngeal and hypophar
Slide 83: Introducing Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are blocked, or when a Portfolio expansion disease or other problem makes normal breathing impossible • Strengthened the
Slide 84: Introducing Interventional Urology
Introducing Key products Interventional Urology • Men’s Health: men with erectile dysfunction. ~25% of men aged 40-70 years old experience moderate to severe erectile dysfunction. • Women’s Health: women with pelvic organ prolapse and stress urinary incontinence. ~50% of women 50- 79 years old repor
Slide 85: Introducing Advanced Wound Dressings
Key products Introducing Advanced Wound Dressings Disease areas Biatain® Superabsorber Biatain® Silicone Fit Biatain® Silicone Non-Border Biatain® Fiber Non-adhesive dressing for Silicone foam dressing for Silicone foam dressing Reinforced gelling fiber. Chronic wounds high volumes of exudate pressu
Slide 86: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Lars Rasmussen Anders Lonning-Skovgaard Dorthe Rønnau Allan Rasmussen Interim President and CEO EVP, CFO EVP, People & Culture EVP, Operations Since 2025 With Coloplast since 2006 With Coloplast since 2022 With Coloplast since 1992 Chronic Care Acute Care New
Slide 87: Income statement
Income statement DKKm Q3 2023/24 Q3 2024/25 Change Revenue 6,885 6,958 1% Gross profit 4,648 4,705 1% SG&A costs -2,551 -2,578 1% R&D costs -240 -239 0% Other operating income/expenses 13 27 nm Operating profit (EBIT) before special items 1,870 1,915 2% Special items -36 -83 nm Operating profit (EBI
Slide 88: Balance sheet
Balance sheet DKKm 30 Jun 2024 30 Jun 2025 Change Balance, total 48,850 47,880 -2% Assets Non-current assets 37,940 37,324 -2% Current assets 10,640 10,556 -1% of which: Inventories 3,676 3,777 3% Trade receivables 4,835 4,789 -1% Marketable securities, cash, and cash equivalents 887 726 -18% Other
Slide 89: Cash flow
Cash flow DKKm 9M 2023/24 9M 2024/25 Change EBIT 5,413 5,477 1% Amortisation 341 369 8% Depreciation 614 646 5% Adjustment for other non-cash operating items -41 113 -376% Change in working capital -1,256 -977 -22% Net interest payments -580 -803 38% Paid tax -3,773 -445 -88% Cash flow from operatio
Slide 90: Manufacturing footprint and COGS categories
Coloplast manufacturing footprint and COGS categories Production by country (Volume)¹ 3% Hungary 10% Isafjordur 0% Costa Rica 13% 0% Hörby China 0% Mørdrup US/France Nieder-Olm Tatabánya Minneapolis Nyirbátor Denmark Porto Sarlat Zhuhai Atos (SE/DE) 74% Kerecis (Iceland) Costa Rica COGS by cost type
Slide 91: Production sites
Production sites Hungary China Tatabánya Zhuhai • Continence care products • Ostomy care products • Ostomy care products • Adhesives • Machine building • Continence care products • Number of employees in production: ~750 • Interventional Urology products • Number of employees in production: ~1,700 C
Slide 92: Production sites
Production sites France Sweden Sarlat Hörby • Disposable surgical urology products • Research & Development centre and • Number of employees in production: ~250 manufacturing of laryngectomy products • Number of employees in production: ~130 US Germany Minneapolis Nieder-Olm • Interventional Urology
Slide 93: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 94: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Simone Dyrby Helvind Kristine Husted Munk Vice President, Investor Relations Senior Manager, Investor Relations Senior Manager, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 2981 Tel. direct: +45
Slide 95: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding